You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

Pulmonology

On demand events

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, and discuss preclinical findings.

MD, PhD, FERS

Klaus Rabe +2 more

On demand materials

Pulmonology

35 min

expert video

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

Learning objectives

Discuss the complexity of inflammatory pathways in COPD and different phenotypes
Provide evidence on the genetic association of IL-33 and COPD and early preclinical results
Discuss outcomes of IL-33 targeting and review the ongoing research in the science behind IL-33 in COPD, including its impact on airway remodeling and disease progression

About these experts

Pulmonology

MD, PhD, FERS

Klaus Rabe

Professor of Pulmonary Medicine | University of Kiel; Director of the Department of Pneumology | LungClinic Grosshansdorf, Kiel, Germany

Pulmonology

MD, MAS

Stephanie Christenson

Associate Professor at the University of California, San Francisco in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine

Pulmonology

Paola Rogliani

Professor, University of Rome 'Tor Vergata, Rome, Italy

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

On demand materials